Additional file 2: of Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines Olga Toro-Salazar Ji Lee Kia Zellars Paige Perreault Kathryn Mason Zhu Wang Kan Hor Eileen Gillan Caroline Zeiss Daniel Gatti Brooke Davey Shelby Kutty Bruce Liang Francis Spinale 10.6084/m9.figshare.6204038.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_of_Use_of_integrated_imaging_and_serum_biomarker_profiles_to_identify_subclinical_dysfunction_in_pediatric_cancer_patients_treated_with_anthracyclines/6204038 Table S1. Plasma analytes assessed in referent normal subjects and in patients undergoing anthracycline therapy. Table S2. Linear regression of biomarkers at V1 to changes in Ejection Fraction > 10% from V1 to V6). (PDF 186 kb) 2018-05-01 05:00:00 Anthracyclines Cardiotoxicity Myocardial strain Global systolic function